Evidence mapPaperPMID 41520794Full record

ReviewThe Journal of infection2026

Early diagnosis and treatment of leptospirosis: Optimizing clinical outcomes.

Umaporn Limothai, Nattachai Srisawat, David A Haake

Abstract readReview
In one paragraph

Review in The Journal of infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Umaporn LimothaiCenter of Excellence in Critical Care Nephrology, Chulalongkorn University, Bangkok, Thailand; Excellence Center for Critical Care Nephrology, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Nattachai SrisawatCenter of Excellence in Critical Care Nephrology, Chulalongkorn University, Bangkok, Thailand; Excellence Center for Critical Care Nephrology, King Chulalongkorn Memorial Hospital, Bangkok, Thailand; Division of Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Academy of Science, Royal Society of Thailand, Bangkok, Thailand; Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, United States of America.
David A HaakeVeterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, United States of America; David Geffen School of Medicine at UCLA, Los Angeles, CA, United States of America. Electronic address: dhaake@ucla.edu.

Funding

Virulence and Adaptation to the Host Environment of Pathogenic LeptospiraP01AI168148 · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2025 to 2025
$2.4M
Identification of predictive biomarkers for severe acute leptospirosis and its long-term sequelaeR01AI183353 · CHULALONGKORN UNIVERSITY · 2025 to 2025
$137k
NIAID NIH HHS P01 AI168148NIAID NIH HHS R01 AI183353
6 · The paper itself

Abstract

Leptospirosis is a globally prevalent zoonotic infection causing more than one million cases and nearly 60,000 deaths annually yet is often diagnosed late after organ dysfunction and other complications have arisen. Delayed diagnosis leads to late initiation of antibiotics and other therapeutic interventions, at which point complications such as renal failure, jaundice, or pulmonary hemorrhage are more common and therapy is less effective. This review highlights the critical importance of early recognition and intervention, emphasizing the therapeutic window during the leptospiremic phase when antibiotics are most effective. We examine the limitations of current clinical and laboratory diagnostic methods, the evolving role of molecular and biomarker-based platforms, and the potential of integrated scoring systems for frontline triage. Evidence supporting early antibiotic therapy, supportive care strategies, and severity prediction tools is summarized. We propose a paradigm shift toward field-adaptable, point-of-care diagnostics and integrated care pathways to ensure earlier treatment, improved outcomes, and reduced global disease burden.

Indexed as

Anti-Bacterial AgentsLeptospirosisAnimalsBiomarkersEarly DiagnosisHumansPrognosisTreatment OutcomeAnti-Bacterial AgentsBiomarkersAnti-bacterial agents/therapeutic useCritical illness/prevention & controlEarly diagnosisLeptospirosisPrognosisRisk assessmentSupportive careTime-to-treatment

Identifiers

PMID41520794
PMCPMC12978856

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.